分子诊断合作与授权协议：2016-2024

Molecular Diagnostics Collaboration and Licensing Deals 2016-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 400+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告审查了 2016 年至 2024 年与分子诊断相关的合作和许可协议，包括协议总数的趋势、财务合约条款、活跃于协议中的主要公司的识别以及合约文件目录等。

主要优点

您可以瞭解 2016 年以来的合约趋势。
您可以查看合作伙伴关係和授权项目。
基准分析：您可以确定合约的市场价值
财务条款：一次性付款、里程碑、特许权使用费
合约目录：依公司名称 (A-Z)、合约类型及处理区域
重大合约：依合约金额
最活跃的合约公司
资产识别和每份合约的合约条款
取得合约文件：深入瞭解合约结构
尽职调查：评估拟议合约条款对合作伙伴公司的适用性
节省数百小时的研究时间

合约分析允许尽职调查：

授予或可选的具体权利有哪些？
合约实际上赋予了合作伙伴公司什么？
授予哪些类型的专有权？
合约的付款结构为
如何审核销售和付款？
合约期限是多久？
合约的主要条款是如何定义的？
如何对待和拥有知识产权？
谁负责商业化？
谁负责开发、供应和製造？
如何管理保密和发布？
如何解决争议
什么情况下可以取消合约？
如果所有者发生变化会怎样？
已就何种类型的分授权或分包条款达成协议？
公司需要哪些样板条款？
哪些样板条款看起来有所不同，取决于合作伙伴和交易类型？
每家公司对合约法拥有哪些管辖权？

This report contains a comprehensive listing of 747 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse molecular diagnostics collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

Trends in molecular diagnostics dealmaking in the biopharma industry
Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
The leading molecular diagnostics deals by value
Most active molecular diagnostics licensing dealmakers
Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

2.1. Introduction
2.2. Molecular diagnostics deals over the years
2.3. Most active molecular diagnostics dealmakers
2.4. Molecular diagnostics deals by deal type
2.5. Molecular diagnostics deals by therapy area
2.6. Molecular diagnostics deals by industry sector
2.7. Deal terms for molecular diagnostics deals
- 2.7.1 Molecular diagnostics deals headline values
- 2.7.2 Molecular diagnostics deal upfront payments
- 2.7.3 Molecular diagnostics deal milestone payments
- 2.7.4 Molecular diagnostics royalty rates